New drug for breast cancer: Promising results of PI3K inhibitor StudyScienceDaily (July 21, 2011), a new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in a phase I study in early phase of testing conducted in the Virginia g. Piper cancer at Scottsdale Healthcare, according to a presentation by an oncologist Dr. Daniel d. Von Hoff at 47? annual meeting of the American Society of Clinical Oncology (ASCO).See also:Health & MedicineGeneLavender oil CancerColon CancerCancerLung breastreferenceCancerPancreatic CancerLeukemia trialMetastasisTumor suppressor clinical
Drugs under investigation, GDC-0941, manufactured by Genentech Inc., South San Francisco, California, is targeting the PI3K, which gene is abnormal in about 20-30 percent of patients with advanced breast cancer.
In collaboration with the Karmanos Cancer Institute in Detroit, Michigan and the Dana Farber Cancer Institute in Boston, Massachusetts, Dr. Von Hoff and his team the Virginia g. Piper Cancer Center Clinical Trials initially tested the drug in 97 patients with various types of advanced cancer. Patients experienced manageable side effects including diarrhea, nausea, taste alteration, rash, itching, vomiting, fatigue, and decreased appetite.
The study resulted in significant tumour shrinkage in patients with advanced cervical cancer and one with advanced breast cancer. Another patient with ampullary cancer of the pancreas is currently in the studio with stable disease for more than a year.
Dr. Von Hoff is physician-In-Chief and distinguished professor at the Translational Genomics Research Institute (TGen), Chief Scientific Officer at Scottsdale Healthcare and us Oncology. Virginia g. Piper cancer center clinical trials is a partnership between Scottsdale Healthcare and TGen which treats cancer patients, with promising new drugs through clinical trials at the Virginia g. Piper Cancer Center at Scottsdale, Arizona
?We are thrilled to tailored treatment for cancer of the breast and gynecological cancer patients PI3K inhibitors,? said Dr. Von Hoff, who made his presentation in June during the ASCO Annual meeting in Chicago. ?The next step will be samples from patients with breast cancer and PI3K for treating those patients accordingly?.
Breast cancer remains one of the most deadly types of cancer among women, with about 180,000 new cases each year.
E-mail or share this story:
walgreens brave alexander skarsgard asteroid virgin america dodgers godzilla
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.